[ad_1]
According to US media reports, at 16 local time, the American pharmaceutical company Moderna said that according to the first analyzes of the phase III clinical trial of the vaccine, the actual rate of the new corona vaccine developed by it was 94.5%.
The company said the preliminary analysis results show that the vaccine poses no major safety risks and is generally well tolerated.
Additionally, Modena also said the company’s vaccine does not require storage at extremely low temperatures. “The vaccine should remain stable at a standard refrigerator temperature of 2 to 8 degrees Celsius for up to 30 days.” “The vaccine can be stored at minus 20 degrees Celsius. The temperature remains stable for up to 6 months; at room temperature, the vaccine can be stored for 24 hours.”
Allegedly, Modena plans to seek authorization for emergency use from the U.S. Food and Drug Administration in the near future. By the end of 2020, the company plans to supply 20 million doses of the vaccine to the US market.
On November 9, local time, BioNTech and Pfizer announced that preliminary results from the Phase III clinical trial of their jointly developed new coronavirus mRNA vaccine demonstrated that the vaccine is effective in preventing infection of the novel coronavirus from healthy individuals. . The efficiency exceeds 90%. (Bioon.com)
.
[ad_2]
Source link